Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate versus deferred sofosbuvir/velpatasvir for hepatitis C in adults with severe mental illness
ACTRN12618001939280Phase 4Terminated
- Sponsor
- University of Adelaide
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sofosbuvir + velpatasvir in hepatitis C virus infection, sponsored by University of Adelaide. Primary endpoint: RBANS total score at week 24. Started Apr 2019; status: terminated.
02
Drugs
sofosbuvir + velpatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ACTRN12618001939280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001939280.